Aurobindo Pharma Ltd has received final approval for Zidovudine capsules USP 100 mg from US FDA.

This approval by US FDA will pave way for the company to market the aforesaid product in the US and also qualify under the President's Emergency Plan for AIDS Relief (PEPFAR) program, stated a release.

This is in addition to having final approval for Zidovudine tablets and oral solutions. The Company is also proud to mention that this is the first generic version final approval for zidovudine capsules USP 100 mg.

Zidovudine is in the class of drugs called nucleoside reverse transcriptase inhibitors (NRTIs), which help keep the AIDS virus from reproducing. It is intended to use with other antiretroviral agents for the treatment of HIV-1 infection.